Tag Archives: Stifel

← Older posts

Akcea, Fresh Off C-Suite Shakeup, Dishes Heart Drug to Pfizer for $250M

Pfizer this morning bought an experimental heart disease drug from Akcea therapeutics, the first move made by the Ionis Pharmaceuticals spinout since the company overhauled its management team last month. Pfizer will pay Akcea (NASDAQ: AKCA) and parent Ionis (NASDAQ: IONS) $250 million up front for rights to AKCEA-ANGPTL3-Lrx, an RNA-based medicine currently in a […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , | Comments Off on Akcea, Fresh Off C-Suite Shakeup, Dishes Heart Drug to Pfizer for $250M

Akcea Shakes Up Management and Shows Three Executives the Door

Akcea Therapeutics has already been struggling to turn its two products into commercial winners. Now it will have to do so during a massive management transition. Akcea (NASDAQ: AKCA) said Monday that CEO Paula Soteropoulos, president Sarah Boyce and chief operating officer Jeff Goldberg have left the company. Akcea’s board of directors has appointed Damien […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, San Diego blog main, San Diego top stories | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on Akcea Shakes Up Management and Shows Three Executives the Door

Acadia Stock Jumps on Positive Dementia-Related Psychosis Drug Data

An Acadia Pharmaceuticals drug that’s already approved for psychosis associated with Parkinson’s disease could soon be heading to an FDA review to expand the use of the drug to dementia patients. On Monday, Acadia (NASDAQ: ACAD) reported that its drug, pimavanserin, met the goal of delaying relapse of psychosis in dementia patients compared to a […]

Posted in National blog main, San Diego, San Diego blog main, San Diego top stories | Tagged , , , , , , , , , , , , | Comments Off on Acadia Stock Jumps on Positive Dementia-Related Psychosis Drug Data

Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles

Jeff Leiden, who helped steer Vertex Pharmaceuticals out of a crisis and into a profitable developer of cystic fibrosis medicines, will step down as the CEO of the Boston company next spring. In a surprising announcement, Vertex (NASDAQ: VRTX) said Thursday morning that Leiden (pictured), who has run the company for about seven years, will […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories | Tagged , , , , , , , , , , , , , , , , , , , , | Comments Off on Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles

As Sangamo Touts Data, BioMarin Preps Hemophilia Gene Therapy For FDA

[Updated 7/8/19, 9:22 am. See below.] Gene therapy for hemophilia is as close as it’s ever been to market. And the race to get there got more heated this past weekend at a medical meeting in Australia. At the International Society on Thrombosis and Haemostasis meeting in Melbourne, Sangamo Therapeutics (NASDAQ: SGMO) and partner Pfizer […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, New York blog main, New York top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , | Comments Off on As Sangamo Touts Data, BioMarin Preps Hemophilia Gene Therapy For FDA

FDA Clears Aerie’s Combo Glaucoma Drug, But Will it Sell?

The FDA late Tuesday approved a new type of glaucoma drug from Aerie Pharmaceuticals that, in clinical testing, beat the generic eye drops known as prostaglandin analogues (PGAs) that are typically prescribed to slow the progression of the disease. Now Aerie (NASDAQ: AERI) will try to prove that the drug can overcome some of its […]

Posted in National blog main, New York, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , | Comments Off on FDA Clears Aerie’s Combo Glaucoma Drug, But Will it Sell?

Data in Hand, Alnylam to Seek OK for Second RNAi Drug

Alnylam Pharmaceuticals this morning released new data that it believes to be good enough to bring the second-ever RNA interference medicine to market, a treatment for a potentially deadly, rare genetic disease called acute hepatic porphyria. Alnylam’s (NASDAQ: ALNY) experimental drug givosiran met its main goal in a 94-patient Phase 3 study called Envision. The […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , , | Comments Off on Data in Hand, Alnylam to Seek OK for Second RNAi Drug

Sunovion’s FDA Rejection Gives Acorda Parkinson’s Drug Breathing Room

The FDA has rejected a Sunovion Pharmaceuticals drug for Parkinson’s disease, delaying the company in its bid to compete with Acorda Therapeutics, which has a similar product that was recently approved for the market. Sunovion said late Wednesday that the FDA asked for more information to support the application for its drug, APL-130277. But the […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , | Comments Off on Sunovion’s FDA Rejection Gives Acorda Parkinson’s Drug Breathing Room

Marinus Claims Phase 2 Postpartum Depression Win, Analysts Less Sure

Marinus Pharmaceuticals says its treatment for postpartum depression (PPD) is showing encouraging results in a mid-stage study—enough to continue clinical development. But it’s unclear whether the results are statistically significant or enough to make the drug competitive against a Sage Therapeutics drug now awaiting an FDA decision for the same condition. Marinus (NASDAQ: MRNS) said […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , | Comments Off on Marinus Claims Phase 2 Postpartum Depression Win, Analysts Less Sure

SuperNus ADHD Drug to Head to FDA, But Is It Better Than a Generic?

An experimental attention deficit hyperactivity drug developed by SuperNus Pharmaceuticals has met the main goals of two late-stage studies, bolstering the company’s case that it could provide an alternative to currently available ADHD therapies. But shares of the Rockville, MD-based company promptly fell on concerns of whether the drug is any better than a widely […]

Posted in Boston blog main, Boulder/Denver blog main, Detroit blog main, Indiana blog main, National, National blog main, National top stories, New York blog main, Raleigh-Durham blog main, San Diego blog main, San Francisco blog main, Seattle blog main, Texas blog main, Wisconsin blog main | Tagged , , , , , , , , , , , , , | Comments Off on SuperNus ADHD Drug to Head to FDA, But Is It Better Than a Generic?← Older posts